Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 1/20 | 0.59 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.59 |
| ▸ | CDK2 | P24941 | 1/20 | 0.59 |
| ▸ | GSK3B | P49841 | 1/20 | 0.59 |
| ▸ | ATR | Q13535 | 8/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.54 |
| ▸ | PRKDC | P78527 | 1/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.48 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3461667 | 0.99 | CCNE2 (0.60) | CCNE2CCNE1CDK2GSK3BATR | |
| SCHEMBL3461069 | 0.94 | PIK3CD (0.54) | CCNE2CCNE1CDK2GSK3BATR | |
| SCHEMBL3462137 | 0.93 | PIK3CD (0.53) | CCNE2CCNE1CDK2GSK3BATR | |
| SCHEMBL3462055 | 0.93 | PIK3CD (0.53) | CCNE2CCNE1CDK2GSK3BATR | |
| SCHEMBL3822499 | 0.92 | PIK3CD (0.52) | CCNE2CCNE1CDK2GSK3BATR | |
| SCHEMBL3460868 | 0.91 | PIK3CD (0.52) | CCNE2CCNE1CDK2GSK3BATR | |
| SCHEMBL3460752 | 0.89 | ATR (0.54) | CCNE2CCNE1CDK2GSK3BATR | |
| SCHEMBL3461832 | 0.89 | PIK3CD (0.49) | CCNE2CCNE1CDK2GSK3BATR | |
| SCHEMBL3462092 | 0.88 | PIK3CD (0.51) | CCNE2CCNE1CDK2GSK3BATR | |
| SCHEMBL3461192 | 0.88 | ATR (0.51) | CCNE2CCNE1CDK2GSK3BATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | claimed |
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| EP-1501514-A4 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1501514-A2 | PROTEIN KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003093297-A2 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211709-A1 | Protein kinase modulators and methods of use | GRK2, MAP4K2, MAPKAPK2 | CCNE2 2303/4885CCNE1 2063/4885CDK2 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.